LitCovid-sentences  

PMC:7283670 / 56355-57928 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T613 0-107 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug:
T614 108-230 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group:
T615 231-286 Sentence denotes 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
T616 287-408 Sentence denotes Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
T617 409-1573 Sentence denotes Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020